Ryoko Yamada

Suita, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 106 publications

On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years.

On-treatment viral factors affect subsequent hepatitis B surface antigen seroclearance in patients treated with nucleos(t)ide analogs for > 10 years.

Journal: Journal of gastroenterology

Published: February 10, 2026

Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Hypertension as an Adverse Event Potentially Impacting the Therapeutic Efficacy of Atezolizumab Plus Bevacizumab in Patients With Unresectable Hepatocellular Carcinoma.

Journal: Journal of gastroenterology and hepatology

Published: March 24, 2025

The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs.

The Risk of Developing Hepatocellular Carcinoma Persists in Chronic Hepatitis B Patients Even After the Long-Term Administration of Nucleos(t)ide Analogs.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: January 06, 2025

Improvement of hepatic reserve and changes in liver and spleen volume after balloon-occluded retrograde transvenous obliteration.

Improvement of hepatic reserve and changes in liver and spleen volume after balloon-occluded retrograde transvenous obliteration.

Journal: BMC gastroenterology

Published: May 21, 2024

Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral.

Thrombospondin-2 as a Predictive Biomarker for Hepatocellular Carcinoma after Hepatitis C Virus Elimination by Direct-Acting Antiviral.

Journal: Cancers

Published: December 03, 2022

Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis.

Fucosylated haptoglobin is a novel predictive marker of hepatocellular carcinoma after hepatitis C virus elimination in patients with advanced liver fibrosis.

Journal: PloS one

Published: September 28, 2022

Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Pretreatment with antibiotics is associated with reduced therapeutic response to atezolizumab plus bevacizumab in patients with hepatocellular carcinoma.

Journal: PloS one

Published: September 06, 2022

Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.

Effect of sofosbuvir and velpatasvir therapy on clinical outcome in hepatitis C virus patients with decompensated cirrhosis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: September 01, 2022

Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy.

Circulating Cell-Free DNA Profiling Predicts the Therapeutic Outcome in Advanced Hepatocellular Carcinoma Patients Treated with Combination Immunotherapy.

Journal: Cancers

Published: June 22, 2022

Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis.

Risk of hepatocellular carcinoma after sustained virologic response in hepatitis C virus patients without advanced liver fibrosis.

Journal: Hepatology research : the official journal of the Japan Society of Hepatology

Published: May 09, 2022

Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.

Serum amyloid P component and pro-platelet basic protein in extracellular vesicles or serum are novel markers of liver fibrosis in chronic hepatitis C patients.

Journal: PloS one

Published: April 07, 2022

Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination-authors' reply.

Letter: serum growth differentiation factor 15 predicts hepatocellular carcinoma occurrence after hepatitis C virus elimination-authors' reply.

Journal: Alimentary pharmacology & therapeutics

Published: April 01, 2022

Showing 1-12 of 106

Last Updated: 09/26/2026